Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection of inflammatory disease and treatment response evaluations using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radio-immunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma, novel α-emitting radionuclide therapies and Selective Internal Radiation Therapy (SIRT) with SIR-Spheres in liver malignancies
Amyloid imaging by 18F-Flutemetamol PET/CT –clinical value and quantitative reference levels
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of tumor heterogeneity and disease patterns
Recent publications
Revheim ME, Alavi A(2021) PET-based Novel Imaging Techniques with Recently Introduced Radiotracers PET Clin, 16(2), xv-xvi DOI 10.1016/j.cpet.2021.01.001, PubMed 33648667
Ayubcha C, Moghbel M, Borja AJ, Newberg A, Werner TJ, Alavi A, Revheim ME(2021) Tau Imaging in Head Injury PET Clin, 16(2), 249-260 DOI 10.1016/j.cpet.2020.12.009, PubMed 33648666
Seierstad T, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Revheim ME, Hernes E(2021) 18F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review PET Clin, 16(2), 167-176 DOI 10.1016/j.cpet.2020.12.012, PubMed 33648662